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The proteolytic activity in tissue extracts, reflected by
acid pH, was described by Hedin in 1904 [1]. In 1928,
the term cathepsin (from the Greek word meaning "to
digest") was introduced by Wilstätter and Bamann [2]
to define the enzyme showing this activity. In 1937,
Anson [3] designed a method for cathepsin purifica-
tion and used hemoglobin as a substrate to determine
its activity. In 1952, lysosomal peptidases were
described and called cathepsin A, B and C [4]. In 1955,
De Duve [5] presented lysosomes as the site of cathep-
sin action. In Poland, cathepsin D and its hemoglobin
substrate were studied by Czystohorski as early as in
the 50s [6]. In 1960, Press et al. [7] used the term
cathepsin D to differentiate it from other endopepti-
dases and exopeptidases. 
At present, cathepsin D (EC 3.4.23.5) is defined as
lysosomal aspartyl endopeptidase. It breaks down pro-
teins into several polypeptide fragments that digest
other lysosomal endopeptidases and exopeptidases.  
Cathepsin D gene
The cathepsin D gene is located at the end of the short
arm of chromosome 11, in the p15.5 region, close to
the H-ras oncogene (Fig. 1). It consists of 9 exons and
contains 11.106 base pairs. For a complete sequence of
cathepsin D gene please refer to paper by Roedecker et
al. [8]. Cathepsin D gene transcription leads to the for-
mation of mRNA containing 1.988 bases. Its expres-
sion is regulated by steroid hormones, growth factors
IGF-1, TNF-α and EGF and by retinoic acid [9-12].
Cathepsin D biosynthesis is inhibited by cyclohex-
imide and colchicine [13-15].
Occurrence, isolation and purification
Cathepsin D can be found in nearly all cells, tissues and
organs, but not in mature lysosome-free erythrocytes
[16]. From tissue homogenate, cathepsin D is isolated
and purified by means of ammonium sulphate saltation,
organic solvent fractionation, molecular gel (sephadex)
chromatography and ion-exchangeable chromatogra-
phy. The terminal stages of purification involve affini-
ty chromatography with application of pepstatin [17-
20], synthetic inhibitors [21], antibodies, cathepsin D
propeptide and hemoglobin [22-24], which are bound
to a constant carrier. Differences in the pH values
between procathepsin D and cathepsin D binding to
pepstatinyl-agarose allowed isolation of these two
forms of the enzyme [25]. Cathepsin D inhibitors can
be isolated by means of cathepsin D bound to a con-
stant carrier [22]. Cathepsin D is also obtained using
genetic engineering techniques [10,26-28].
The method of cathepsin D isolation from the
human liver [29-33], spleen [18], brain [37], uterus
[34], placenta [35], gastric mucosa [36], thyroid [38]
and leucocytes [39] has been described.  The human
liver cathepsin D preparation is produced by Cal-
biochem and Sigma. 
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Review article
Thanks to the disordered structure of the polypeptide
chain (in approximately 70%) and the presence of four
disulphate bridges and eight oligosaccharide chains,
cathepsin D is well soluble and resistant to denaturating
agents and proteolytic degradation [40-42].
Biosynthesis 
Cathepsin D is synthesized in the form of prepro-
cathepsin [33,43-46] by the mRNA bound to the rough
endoplasmic reticulum (RER). Translocation of prepro-
cathepsin D to the cisterns of the endoplasmic reticu-
lum (ER) is possible due to a signal sequence [47,48].
A signal recognition particle (SRP) binds to the
sequence, at the same time blocking protein translation.
Then, the SRP binds to its receptor, located in ER,
which reactivates translation (Fig. 2). Binding of the
SRP-receptor initiates the formation of hydrophylic
protein channel in the ER membrane. Next, the SRP
detaches from the complex and returns to the cyto-
plasm. Simultaneously, ribosomes bind to proteins of
the ER membrane. The elongating polypeptide chain is
introduced through the channel in the ER membrane to
the cisterns due to a 20 amino acid sequence situated at
the N-terminus. At the end of this channel, signal pep-
tidase in ER cisterns cuts off the signal sequence, thus
leading to the generation of procathepsin D that enters
the ER cisterns. The signal sequence that has been
detached undergoes degradation to amino acids. The
amino acid sequence of procathepsin D determines its
posttranslatory modifications: particle rugosity, forma-
tion of disulphate bridges, N-glycosylation and phos-
phorylation. About 5% of the polypeptide chain of pro-
cathepsin D has an alpha-helix conformation, 26% -
beta conformation (rugose sheet), and the remaining
part being a disordered structure. Disulphate bridges
are formed between the cysteine residues Cys27-
Cys96, Cys46-Cys53, Cys222-Cys226 and Cys265-
Cys302, their location being determined by protein-
disulphide isomerase (PDI). The N-glycosylation site is
constituted by the Asn70 residue (heavy chain) and
Asn199 residue (light chain) of the molecule.  
Glycosylation
The oligoglycosylation chains are synthesized with the
involvement of dolichol phosphate and then trans-
ferred onto asparagin residues [46,78], located on the
triad sequences: Asn70-Gly71-Thr72 and Asn199-
Val200-Phe201. The remaining 9/11 asparagin
residues are not found on these sequences and are sub-
ject to glycolysation. Cathepsin D contains eight vari-
ous mannose type oligosaccharide chains in the parti-
cle (Fig. 3). Five of them bind to the residue Asn-70 of
the light chain and contain 3, 5, 6 or 7 mannose
residues. All of them contain two GlcNAc, one has
three GlcNAc residues. Three oligosaccharides bind to
the residue Asn199 of the heavy chain and contain 5
mannose residues. One of them has three GlcNAc
residues, one contains fucose and one has galactose.
Each oligosaccharide chain contains two N-acetylglu-
cosamine molecules, whereas two of them have 3 mol-
ecules and from 3 to 7 mannose residues. 
The phosphate acid residue is attached to the sixth
carbon of mannose [81], which conditions binding to
the mannose-6-phosphate receptor and translocation of
cathepsin D to primary lysosomes. The GlcNAc
residues found outside the oligosaccharide chain are
not subject to phosphorylation and are not involved in
the transport of cathepsin D. 
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Fig. 1. Cathepsin D gene, GeneID: 1509 (description in text).
Fig. 2. Biosynthesis of preprocathepsin D (PPCD); synthesis and
postralationnal modification of procathepsin D (PCD). K - endo-
plasmic reticulum membrane channel; P - PS cleaving protease;
PCD - procathepsin D;PPCD - preprocathepsin D; PS - signaling
peptide; PT - transport vesicle; RER - rough endoplasmic reticu-
lum; SP - signal peptidase; SRP - signal-recognition particle; SRP-
R - SRP receptor.
Phosphorylation and binding to the receptor
The cis zone of the Golgi apparatus captures ER-
derived transport vesicles that contain glycosylated
procathepsin D, which is then transferred to its central
and trans zones. In the trans zone, terminal mannose
residues undergo phosphorylation to mannose-6-phos-
phate (M6P) [53,54]. By means of M6P residues, pro-
cathepsin D binds to mannose-6-phosphate receptors
(M6PR) and in the form of vesicles is transported to
primary lysosomes [55-60]. Primary lysosomes are
formed by budding off from the membrane fragment
of the smooth endoplasmic reticulum. The  mannose-
6-phosphate receptor (M6PR) is a heterogenic protein
and occurs in two types: M6PR-46 and M6PR-300.
The action of M6PR-46 (46 kDa) depends on the pres-
ence of bivalent cations, whereas that of M6PR-300
(300 kDa) is not bivalent cation-dependent. In the acid
environment of primary lysosomes (pH=4.5-5.5), the
procathepsin D M6P-M6PR complex undergoes disso-
ciation. The receptor returns to the Golgi apparatus and
transports M6P molecules of procathepsin D, whereas
the receptor-free procathepsin D remains in lysosomes
and undergoes dephosphorylation. The mannose-6-
phosphate receptors occur in the trans-Golgi network
and in primary lysosomes, but not in mature lyso-
somes. These differences help distinguish primary
from mature lysosomes. 
Proteolytic transformations 
Preprocathepsin D is composed of 412 amino acid
residues [63-68]. In its molecule, signal protease
cleaves the peptide bond Ala20-Leu21 and 20-amino
acid prepeptide is split off (Fig. 4), giving rise to pro-
cathepsin D, built up of 392-amino acid residues. Its
autocatalytic activation takes place in primary lyso-
25Human cathepsin D
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2008:46(1): 25 (23-38) 
doi: 10.2478/v10042-008-0003-x
Fig. 3. Oligosaccharide chains found in cathepsin [51]; (A) oligosaccharides linked with Asn70 in the heavy chain; (B) oligosaccha-
rides linked with Asn199 in the light chain. Asn - asparagine, Fuc - fucose, Gal - galactose, GlcNAc - N-Acetyl-D-glucosamine, Man
-  mannose.
Fig. 4. Cathepsin D prepeptide (signaling sequence).
somes, in an acidic pH (Fig. 5). Intracellular cleavage of
the Glu64-Gly65 bond and splitting-off of 44-amino
acid propeptide occur (Fig. 6). An active mono-chain
form of cathepsin D, composed of 348 amino acid
residues, is generated (Fig. 7). The enumeration of
amino acid residues of the mono-chain cathepsin D
(from 1 to 348) has been used for tracing further trans-
formations in the polypeptide chain.  A non-defined
endopeptidase cleaves the -Val6-Leu7- bond and the 6-
amino acid fragment of the Ser-Ala-Ser-Ser-Ala-Val
sequence is split off, giving rise to a molecule built up
of 342 amino acid residues. The aminopeptidase cleaves
the Leu7-Lys8- bond and a leucine residue is split off. A
modified mono-chain cathepsin D molecule, composed
of 341 amino acid residues, is produced, in which cys-
teine endopeptidase cleaves the -Ala204-Tyr205- bond.
A two-chain cathepsin D molecule is produced, with no
change in the number of amino acid residues. The heavy
chain contains 204, whereas the light chain - 137 amino
acid residues. Inhibitors for cysteine proteinases prevent
this transformation [43,69,70]. Carboxypeptidase
cleaves the Lys203-Ala204 bond and the Ala204 residue
is split off the heavy chain C-terminus. Aminopeptidase
cleaves the Tyr205-Trp206 bond and the Tyr205 residue
is split off the light chain N-terminus. Carboxypepti-
dase cleaves in turn the Arg347-Lys348 and then
Ala346-Arg347 bonds and the residues Lys348 and
Arg347 are split off the C-terminus of the light subunit.
These protease inhibitors suppress cathepsin D matura-
tion. The ultimate form of mature two-chain cathepsin
D is composed of 337 amino acid residues. The heavy
chain contains 196 and the light chain has 141 amino
acid residues. These chains are linked by hydrophobic
bonds (Fig. 8). The amino acid composition shows a
substantial content of glycine and an approximately
twofold level of dicarboxy amino acids and their amides
as compared to alkaline amino acids (Table 1).
The proteolytic activation of procathepsin D via
limited proteolysis is an irreversible process. An ulti-
mate cathepsin D molecule has an approximate double
symmetry. The proteolytic activity of the mono-chain
and two-chain forms is the same (Fig. 9).
Proteolytic modifications of the molecule and
diversity of oligosaccharide composition contribute to
a marked molecular heterogenicity of cathepsin D
[17,29,37,71,72].
Substrate specificity
Cathepsin D cleaves peptide bonds inside the polypep-
tide chain. These bonds are formed mainly by carboxyl
groups of hydrophobic amino acids, especially aro-
matic amino acids [73,74].
Research studies performed with synthetic peptides
(general formula Fig. 10) have provided information
on the structure of the catalytic site of cathepsin D and
the requirements each substrate should fulfill. The
peptides contain different amino acid residues at posi-
tions X and Y. Only the peptides that have amino acids
with ramified chains in the X-position are resistant to
hydrolysis. Those containing at least five amino acid
residues in a molecule are sensitive to cathepsin D
effect. In the hexapeptide containing the sequence of
Gly1-Phe2-Phe3-Tyr4-Thr5-Pro6-Lys7, cathepsin D
cleaves two peptide bonds between Phe2-Phe3 and
Phe3-Tyr4, whereas in the heptapeptide Phe1-Gly2-
His3-Nph4-Phe5-Val6-Leu7-OMe the bond between
Nph4-Phe5 is cleaved [76]. In micromolecular syn-
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Fig. 5. Autoactivation of procathepsin D;  (a) conformational changes and formation of catalytic site (formed by Asp33 and Asp231); 
(b) autoactivation, splitting-off of activating peptide.
Fig. 6. Cathepsin D propeptide.
thetic substrates the number of peptide bonds cleaved
by cathepsin D is considerably smaller even though
they are formed by the same amino acid residues. The
differences are due to additional sites in the enzyme
molecule that bind macromolecular substrates [74,77].
In the oxidized insulin chain B, cathepsin D
cleaves five peptide bonds, whereas all proteases of
lysosomal extracts cleave as many as 27/29 peptide
bonds in this polypeptide (Fig. 11). The peptide bonds
cleaved by cathepsin D in some proteins have been
presented in Table 2. 
Mechanism
The catalytic site of cathepsin D is constituted by two
asparagine acid residues - Asp33 and Asp231, located
in the triad sequences of Asp-33-Thr34-Gly35 and
Asp31-Thr232-Gly233 [80]. In the acidic environ-
ment, the carboxyl group of Asp33 undergoes dissoci-
ation, whereas that of Asp231 does not. The carboxyl
group of Asp33 activates the water molecule and
allows proton release from this molecule. However,
the protonated carboxyl group of Asp231 polarizes the
carbonyl group of the peptide bond, facilitates forma-
tion of a tetraedric intermediate and allows cleavage of
the bond. The reactions are performed by ionizing
groups of cathepsin D and therefore their velocity is
pH-dependent. Cathepsin D shows the highest activity
in an acidic pH (pH=3.5-5.5). 
Hydrolysis of the peptide bonds catalyzed by
cathepsin D occurs in two stages and can be expressed
as a general formula (Fig. 12). In the first stage, the
27Human cathepsin D
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2008:46(1): 27 (23-38) 
doi: 10.2478/v10042-008-0003-x
Fig. 7. Aminoacidic sequence of
human, single-chain cathepsin D [46];
* -  catalytic site - Asp33 and Asp231
residues; ? - catalytic site Asn70 and
Asn199 with added oligosaccharide
chains.
enzyme (E) binds water and with a substrate (S) forms
the enzyme-substrate complex (E-S), in which the
components are bound by ionic and hydrogen bonds.
Conformatory changes, intramolecular electron and
proton regrouping within the peptide bond are
observed, and a covalent intermediate compound (E-
S') is formed. The intermediate compound is an
aminoacyl enzyme. In the next stage, the intermediate
compound undergoes breakdown, accompanied by the
release of the first (R1) and the second (R2) reaction
products. 
The action of cathepsin D takes place not only with
the involvement of asparagine acid residues but also
with other amino acid residues, and it thus has a mul-
tifunctional and intracellular character. Multifunction-
al catalysis is based on simultaneous effects of nucle-
ophylic and electrophylic groups of the enzyme cat-
alytic site on the carbonyl group of the peptide bond.
Attachment of the substrate is followed by two syn-
chronized transfer reactions: in the first, the proton is
transferred from a water molecule onto a carboxyl
anion of Asp33, in the other, the proton derived from a
carboxyl group of Asp231 is transferred onto the oxy-
gen of the carbonyl group of the substrate, giving rise
to a tetraedric intermediate [81-86].
Two protons are simultaneously transferred onto
the peptide bond (Fig. 13a). The first originates  from
the water molecule activated by Asp33. The other is
derived from the carboxyl group of Asp231 and is car-
ried onto the oxygen atom of the carbonyl group of the
peptide bond. These two transfers lead to the formation
of an aminoacyl enzyme, being a tetraedric intermediate
(Fig. 13b), sensitive to the action of the activated water
molecule. The subsequent double proton transfer causes
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Fig. 8. Proteolytic modification of procathepsin D. PS - signaling
peptide, EP - endopeptidase, AP - aminopeptidase, EPc - cysteinyl
endopeptidase, CP - carboxypeptidase,    - hydrophobic bond.
Fig. 9. 3D structure of human cathepsin D in active (A) [171] and
inactive form (B) in pH=7.5 [172].
Fig. 10. Amino acid sequence pattern common for oligoproteins
that are preferentially cleaved by cathepsin D [75].
breakdown of the tetraedric intermediate (Fig. 13c). The
intra- and mono-molecular character ensures the maxi-
mum concentration of the catalytic groups, their optimal
direction and spatial distribution. In consequence, these
processes reduce the activation energy (Fig. 14).  The
peptide bond of the C-N substrate is broken down,
which gives rise to the first product of reaction with a
free carboxyl group (R1) and to an aminoenzyme. Then,
the second product of reaction with a free amine group
is released (R2). The catalytic site of cathepsin D
changes into the anhydride form, which undergoes rapid
hydrolysis and is thus reproduced as the primary struc-
ture of the catalytic site. 
Pepstatin, a pentapeptide containing statin at posi-
tion 4 (Sta4) was used to investigate the structure of the
catalytic site. The Sta4 residue is a structural analog of
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Table 1. Amino acid composition of different molecular forms of cathepsin D.
*calculated from amino acid composition, without sugar moieties.
Fig. 11. Cleavage of B-chain of insulin by cathepsin D and lysosomal extracts [78,79].
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Fig. 12. Simplified diagram present-
ing hydrolysis of peptide bond.
Fig. 13. Cathepsins D mechanism of action: (a) transfer of two protons, (b) formation of tetraedric intermediate, (c) breakdown of the
tetraedric intermediate.
Table 2. Preferential cleavage sites in various protein substrates found upon mild cleavage by cathepsin D [75]. Homologous amino acid
residues at the various positions are enclosed by boxes.
the substrate and of the transitory state, and exerts an
inhibitory effect due to structural similarity to the
tetraedric intermediate, formed during cleavage of pep-
tide bond by asparagin acid residues of the catalytic site
(Fig. 15). The interaction of cathepsin D with pepstatin
is illustrated by a spatial model (Fig. 16).   
Activators and inhibitors
The activity of cathepsin D is increased by glycine
ethyl ester [90], phospholipids [91], polyphosphates
[92] and probably by a protein activator (20000 Da)
isolated from the spleen [93]. The role of activating
compounds in studies on cathepsin D is slight. 
No typical cell cathepsin D inhibitors have been
revealed. The inhibitory effect is demonstrated by a
propeptide split off during procathepsin D autoactiva-
tion [73,94,95] and by respective fragments of its
structure [96]. Alpha2-macroglobulin is an endoge-
nous plasma inhibitor of this protease [97,98]. The
activity is also suppressed by antibodies [99,100],
some glycosaminoglycans [101] and fragments of
DNA structure [102]. 1,2-epoksy3-(p-nitrofenyloksy)-
propan reacting with Asp33 [103] and methyl ester of
diacetylo-DL-norleucine reacting with Asp231 are the
synthetic inhibitors of cathepsin D [104]. Cathepsin D
inhibitors, called pepstatins, are synthesized by bacte-
ria of the genus Streptomyces [105-107]. Polypeptide
inhibitors of this proteinase occur in spare organs of
many plants [108] and in tissues of some lower ani-
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Fig. 14. Diagrammatic representation of the free activation energy
of peptic bond hydrolysis catalyzed by cathepsin D. E - enzyme, S
- substrate, E-S enzyme-substrate complex, T1, T2 - tetraedric
intermediate, P - product. Upper line - non-catalyzed reaction,
lower line - catalyzed reaction. 
Fig. 15. Sta4 structural analogy to transition state of cathepsin D
[83].
Fig. 16. Schematic diagram of the pepstatin
A binding site in cathepsin D [89].
mals [109,110]. Cathepsin D inhibitors have played a
substantial role in the studies concerning the structure
and mechanism of action of this protease and its tissue
location [111-115].
The effects of cathepsin D also depend on the struc-
ture of substrate protein. Denaturated or heme-free
hemoglobin shows increased susceptibility to the
action of this proteinase as compared to native hemo-
globin [18]. However, hemoglobin complexification
with haptoglobin reduces its susceptibility to cathepsin
D [116].
Role in protein degradation 
Cathepsin D takes part in digestion of exhausted and
denaturated cell proteins or proteins showing abnor-
mal structure and those which entered the cell via
endocytosis [14,25,26,96]. It initiates proteolytic
degradation of proteins, cleaving it into large frag-
ments. This causes increased accessibility of the sub-
sequent peptide bonds and thus they are further digest-
32 A. Minarowska et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2008:46(1): 32 (23-38) 
doi: 10.2478/v10042-008-0003-x
Fig. 17. Site of enzymes action on proteoglycans [121]. o–o–o pro-
tein core; •-•-• polysaccharide chain; C - cathepsin D; H -
hialuronidase; X - β-xylosidase.  
Table 3. Comparison of proteolytic activity of cathepsin D in
degradation of various proteins [139].
Fig. 18. Activation of proenzymes
and inactivation of proteinase
inhibitors by cathepsin D [123-
128].
ed by other lysosomal proteins to dipeptides and amino
acids. Cleavage of even a single peptide bond in a pro-
tein molecule may cause its structural denaturation and
functional inactivation. The state of the protein mole-
cule (native, denaturated) defines accessibility of the
protease peptide bonds. In proteoglycans, cathepsin D
cleaves peptide bonds located in the central part of the
polypetide chains (Fig. 17), which results in the for-
mation of large peptide glycan fragments. Collagen is
also sensitive to the action of cathepsin D [122].
Cathepsin D also performs a limited proteolysis,
referring to single peptide bonds, thus leading to the
activation of proenzymes of certain proteases and inac-
tivation of their inhibitors (Fig. 18). It is also involved
in the conversion of prohormones and precursor forms
of biologically active peptides to active forms [132]
and contributes to their inactivation. (Table 3).  From
hemoglobin, cathepsin D releases biologically active
hemorphins [131,132]. Thus, it plays a regulatory role. 
The optimum pH for the action of cathepsin D
bound to the lysosomal membranes is higher as com-
pared to the free enzyme [133]. Also cathepsin D
bound in vitro by a constant carrier shows higher pH
optimum [134]. A small amount of cathepsin D can be
found on cell surface, due to the fusion of lysosomes
with the plasma membrane, it also enters the intercel-
lular environment and passes to the blood [135]. 
Determination of cathepsin D activity and
concentration
Cathepsin D does not need activators in order to act
and has no endogenous inhibitors. Procathepsin D
present in a sample undergoes rapid autoactivation in
test conditions (pH=3.5-4.0) and therefore total activi-
ty of cathepsin D can be determined in the material
examined. Bovine globin [136,137] and bovine hemo-
globin [138] are most sensitive to cathepsin D action.
The enzyme activity is reflected by the quantity of
TCA-soluble tyrosine released from these substrates.
Cathepsin D shows a considerably lower affinity as
compared to other proteins (Table 3). The activity of
this protease is also determined using micromolecular
synthetic substrates [140-143].
The content of active cathepsin D in tissue
homogenates in blood plasma and body fluids is deter-
mined by means of a graph showing the relationship
between the activity and the level of highly-purified
cathepsin D preparation [144] (Fig. 19). Another
method employed to assess cathepsin D content is titra-
tion of the catalytic site using pepstatin and its deriva-
tives [107,145] (Fig. 20). Pepstatin binds to cathepsin D
in the mole ratio of 1:1. The total content of cathepsin
D, inactive and active in tissues and body fluids, is
determined by means of specific antibodies  [18,146].
Cell and tissue localization of cathepsin D is per-
formed using the immunohistoenzymatic methods, with
specific antibodies [147-150] or labeled pepstatin [151-
153].
Differences in substrate specificity, pH optima, sen-
sitivity to activators and inhibitors, and in antigen prop-
erties allow identification of cathepsin D and determi-
nation of its activity and concentration in tissue
homogenates, blood plasma and body fluids [154-157].
Final comments
Cathepsin D plays an essential role in metabolism as
an enzyme degrading the exhausted cell proteins and
restoring their amino acids to syntheses, as well as a
modulator of proteolysis, activating precursor forms of
many proteases and inactivating their inhibitors. The
role of cathepsin D in biomedical sciences extends its
involvement in many pathological processes such as
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Fig. 19. The relationship between the hydrolysis of hemoglobin by
cathepsin D on the amount of enzyme.  
Fig. 20. Inhibitor curve obtained by addition of increasing
amounts of pepstatin to the cathepsin D; substrate - hemoglobin;
titration curve: a - ideal, b - real.
apoptosis, inflammatory states, rheumatic diseases,
neoplasms, muscle dystrophy, Alzheimer disease, as
well as in their diagnostics [158-168]. The use of
inhibitors of cathepsin D biosynthesis, activation and
its active form allows regulation of cathepsin D acti-
vation. 
Human preprocathepsin, procathepsin and cathep-
sin D differ from their equivalents isolated from the
mammalian tissue in a number of particulars concern-
ing the amino acid sequence, posttranslatory modifica-
tions and conformatory structure [169]. Due to the dif-
ferences, human anti-cathepsin D antibodies do not
react with cathepsin D of other species [170]. 
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